Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Fax: 781 275 7562

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

HedgeAlerts Nov. 14 at 6:53 PM

Hedge Alert Live - Protect Your Portfolio Contract: $OCUL $11.00 Put · NOV 21, 2025 Exp Entry Price: $0.25 - $0.35 Exit Price Target: $0.51 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 14 at 8:13 AM

Hedge Alert Live - Protect Your Portfolio Contract: $OCUL $11.00 Put · NOV 21, 2025 Exp Entry Price: $0.25 - $0.50 Exit Price Target: $0.52 Profit Margin: +107% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

rizzato Nov. 11 at 4:31 PM

$OCUL both company ocul and eypt are moving 0 volume today , it seems they moved on the same way during the week

0 · Reply

LiquidThetaOptions Nov. 9 at 11:29 AM

💎 LiquidTheta® Live Actionable Trade Asset: $OCUL Contracts: $OCUL January 15, 2027 $12 Calls Scale in: $3.84- $4.69 Scale out: $14.92-$25.57 Profit Potential : 247% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

esu89 Nov. 7 at 7:57 PM

$OCUL Big sigh. The hand wringing continues. I take comfort in management continuing to be VERY optimistic in public presentations & saying that everything they do is done with confidence. This management group did not have to get involved here. They elected to get involved, some coming out of retirement to do so. I take even greater comfort with large institutional investors like Fidelity taking monster size positions & taking large increases in existing positions. They know more than we do & rarely swing & miss with large investments like we have seen over the course of the last year. As to the raise, my belief is that it was done for one of two reasons. First, it may have been a defensive move to fend off a lowball offer(s) before SOL-1 results are announced. Second, it may have been because of all the uncertainty that exists in the macro environment. Personally, I think we are in for a very rough 12 to 24 months. Maybe both were factors. Only time will tell. Know what you own.

1 · Reply

rizzato Nov. 7 at 5:26 PM

$OCUL \ ocul and eypt are in the same boat similar product many upgrades but both down. in the share price

0 · Reply

highkick Nov. 7 at 4:36 PM

$OCUL I'm not concerned about the short term price ,as we will find out in the next 4 months if our waiting was validated or not . Also lets hope Fidelity is proved right with its recent purchase of another 12 million shares bringing its total to 31.7 m shares.

0 · Reply

Fairvalue10 Nov. 7 at 3:17 PM

$OCUL Free fall

0 · Reply

SawickiCapital1 Nov. 7 at 3:06 PM

$OCUL forget $10.25…I’m going to wait for $9. It’ll go there. Big time slip up from the c-suite.

2 · Reply

ZackInvest008 Nov. 7 at 3:40 AM

$OCUL consensus here seems to be this is dead money for a couple years?

2 · Reply

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:05 AM EST - 10 days ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 10 days ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 5 weeks ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 1, 2025, 4:22 AM EDT - 6 weeks ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Sep 30, 2025, 7:08 AM EDT - 6 weeks ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 6 weeks ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 8, 2025, 5:05 PM EDT - 2 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 1:52 AM EDT - 2 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Aug 5, 2025, 1:33 PM EDT - 3 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Jun 26, 2025, 1:54 PM EDT - 5 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 5 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 14, 2025, 7:00 AM EDT - 6 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Apr 11, 2025, 4:30 PM EDT - 7 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 11, 2025, 2:49 PM EDT - 8 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 6, 2025, 11:15 AM EST - 9 months ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 3, 2025, 10:16 AM EST - 9 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 7:00 AM EST - 9 months ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 10 months ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 10 months ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 11 months ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 2:01 PM EDT - 1 year ago

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Jun 1, 2024, 5:30 AM EDT - 1 year ago

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 6, 2024, 8:16 PM EDT - 1 year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 3, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

HedgeAlerts Nov. 14 at 6:53 PM

0 · Reply

HedgeAlerts Nov. 14 at 8:13 AM

0 · Reply

rizzato Nov. 11 at 4:31 PM

$OCUL both company ocul and eypt are moving 0 volume today , it seems they moved on the same way during the week

0 · Reply

LiquidThetaOptions Nov. 9 at 11:29 AM

0 · Reply

esu89 Nov. 7 at 7:57 PM

1 · Reply

rizzato Nov. 7 at 5:26 PM

$OCUL \ ocul and eypt are in the same boat similar product many upgrades but both down. in the share price

0 · Reply

highkick Nov. 7 at 4:36 PM

0 · Reply

Fairvalue10 Nov. 7 at 3:17 PM

$OCUL Free fall

0 · Reply

SawickiCapital1 Nov. 7 at 3:06 PM

$OCUL forget $10.25…I’m going to wait for $9. It’ll go there. Big time slip up from the c-suite.

2 · Reply

ZackInvest008 Nov. 7 at 3:40 AM

$OCUL consensus here seems to be this is dead money for a couple years?

2 · Reply

TickrTalk0007 Nov. 6 at 10:45 PM

$OCUL If this company gets overvalued on the market cap, then there wont be any buyer for it. big pharma will buy for no more than $2-$3 billion after Ph 3 data from both studies....if they show $1 billion in sales in 2-3 years post-approval, then $5-$6 billion buyout....but expect more dilution

1 · Reply

SawickiCapital1 Nov. 6 at 8:09 PM

$OCUL fwiw, I’ve never seen a stock perform so poorly after multiple upgrades. My guess is the market sees through these “upgrades”.

1 · Reply

SmokenTuna Nov. 6 at 2:50 PM

$OCUL we all ready for a decent run.. any time now.

0 · Reply

Fairvalue10 Nov. 6 at 12:03 PM

$OCUL All the analysts are raising their targets, yet we are continuously declining.

3 · Reply

IN0V8 Nov. 6 at 5:33 AM

$OCUL Buy RBC raises target price to $24 from $17

0 · Reply

TickrTalk0007 Nov. 6 at 12:18 AM

$OCUL only winners in the $450M offering were underwriters.

0 · Reply

TickrTalk0007 Nov. 6 at 12:17 AM

$OCUL turns out underwriters bought at $11.77 and not $12.53 as the offering says

0 · Reply

Windy007 Nov. 5 at 8:15 PM

$OCUL RBC Capital models $7 billion revenue in 2035 and EPS over $16. What’s the value of the stock with those numbers? Just a “tad” more than where it is now….like $300 more

1 · Reply

highkick Nov. 5 at 7:53 PM

$OCUL fidelity owns 31.7 m shares now .

0 · Reply

The_Mighty_Tior Nov. 5 at 5:34 PM

$OCUL (Monthly log) Is this going to $40 or 2? Victory here would look like skimming over/through the next yellow triangle and surviving the orange trap door chutes...which means a channel breakout or better yet, holding above the black curve by summer. The first sign of trouble would be losing the monthly 9MA @ $10 / a failed breakout of the blue zone.

0 · Reply

Quantumup Nov. 5 at 3:25 PM

RBC Capital⬆️ $OCUL's PT to $24 from $17, reiterated at Outperform, and said, wAMD Pivotals Full Steam Ahead, DR May Offer Additional Upside Potential. $EYPT $FDMT $REGN $RHHBY RGNX RBC Capital additionally said:

0 · Reply

The_Fact_ster Nov. 5 at 3:23 PM

$OCUL we appear to be getting that pullback. Gonna be a little cautious as we may fall back to 9s before data if bios trade choppy in the short term.

0 · Reply

Market Cap	2.45B
Revenue (ttm)	63.72M
Net Income (ttm)	-193.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-303.69%
Debt to Equity Ratio	0.27

Volume	1,339,900
Avg Vol	2,831,414
Day's Range	N/A - N/A
Shares Out	213.05M
Stochastic %K	63%
Beta	1.53
Analysts	Strong Sell
Price Target	$22.08